In vitro measurement of enzymatic markers as a tool to detect mouse cardiomyocytes injury

Souza, Elen Mello de; Henriques-Pons, Andréa; Bailly, Christian; Lansiaux, Amélie; Araujo-Jorge, T. C.; Soeiro, Maria de Nazaré Correia

doi:10.1590/s0074-02762004000700006

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absorbance was measured at a wavelength of 490 nm with a spectrophotometer (VersaMax tunable microplate reader; Molecular Devices), which allows for the determination of LC 50 s (drug concentrations that reduce 50% of cellular viability). Additionally, cellular viability was monitored through creatine kinase cardiac isotype (CK-MB) levels released into the supernatant of untreated and DB766-treated CM, as reported previously (62).…”

Section: Methodsmentioning

confidence: 99%

Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease Treatment

Batista

Oliveira

et al. 2010

Antimicrob Agents Chemother

195

View full text Add to dashboard Cite

Chagas' disease, a neglected tropical illness for which current therapy is unsatisfactory, is caused by the intracellular parasite Trypanosoma cruzi. The goal of this work is to investigate the in vitro and in vivo effects of the arylimidamide (AIA) DB766 against T. cruzi. This arylimidamide exhibits strong trypanocidal activity and excellent selectivity for bloodstream trypomastigotes and intracellular amastigotes (Y strain), giving IC 50 s (drug concentrations that reduce 50% of the number of the treated parasites) of 60 and 25 nM, respectively. DB766 also exerts striking effects upon different parasite stocks, including those naturally resistant to benznidazole, and displays higher activity in vitro than the reference drugs. By fluorescent and transmission electron microscopy analyses, we found that this AIA localizes in DNA-enriched compartments and induces considerable damage to the mitochondria. DB766 effectively reduces the parasite load in the blood and cardiac tissue and presents efficacy similar to that of benznidazole in mouse models of T. cruzi infection employing the Y and Colombian strains, using oral and intraperitoneal doses of up to 100 mg/kg/day that were given after the establishment of parasite infection. This AIA ameliorates electrocardiographic alterations, reduces hepatic and heart lesions induced by the infection, and provides 90 to 100% protection against mortality, which is similar to that provided by benznidazole. Our data clearly show the trypanocidal efficacy of DB766, suggesting that this AIA may represent a new lead compound candidate to Chagas' disease treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease Treatment

Batista

Oliveira

et al. 2010

Antimicrob Agents Chemother

195

View full text Add to dashboard Cite

show abstract

Mode of action of a novel anti-Listeria bacteriocin (CAMT2) produced by Bacillus amyloliquefaciens ZJHD3-06 from Epinephelus areolatus

Liu

et al. 2018

Arch Microbiol

View full text Add to dashboard Cite

Bacteriocin CAMT2, produced by Bacillus amyloliquefaciens ZJHD3-06, has been shown to exhibit protective activity against important food spoilage and food-borne bacterial pathogens. This study was conducted to investigate the mode of action of bacteriocin CAMT2 against highly pathogenic Listeria monocytogenes ATCC 19111. The addition of bacteriocin CAMT2 at 64 AU/ml inhibited L. monocytogenes ATCC 19111. An efflux of K ions, lactic acid dehydrogenase and an increase in extracellular electrical conductivity was observed in CAMT2-treated L. monocytogenes. Electron microscopy showed morphological alterations such as uneven cell surface, accumulation of cell debris and bacterial lysis. These results show that bacteriocin CAMT2 inhibit L. monocytogenes by increasing cell permeability and inducing membrane damage, hence it has the great application potentials in ensuring food safety.

show abstract

Lycium barbarum polysaccharide antagonizes cardiomyocyte apoptosis by inhibiting the upregulation of GRK2 induced by I/R injury, and salvage mitochondrial fission/fusion imbalance and AKT/eNOS signaling

Yang

Zhang

et al. 2022

Cellular Signalling

View full text Add to dashboard Cite

In vitro measurement of enzymatic markers as a tool to detect mouse cardiomyocytes injury

Cited by 5 publications

References 13 publications

Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease Treatment

Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease Treatment

Mode of action of a novel anti-Listeria bacteriocin (CAMT2) produced by Bacillus amyloliquefaciens ZJHD3-06 from Epinephelus areolatus

Lycium barbarum polysaccharide antagonizes cardiomyocyte apoptosis by inhibiting the upregulation of GRK2 induced by I/R injury, and salvage mitochondrial fission/fusion imbalance and AKT/eNOS signaling

Contact Info

Product

Resources

About